Omid Yazdanpanah, MD, on Metastatic Castration-Resistant Prostate Cancer: LuPSMA With or Without ARPIs

February 19, 2025 By The ASCO Post Staff

Omid Yazdanpanah, MD, of the University of California, Irvine, presents findings from a secondary analysis of the VISION trial, which compared the efficacy and safety of LuPSMA in patients treated with vs without concomitant androgen receptor pathway inhibitors (ARPIs) (Abstract 121).

Related Content